Teladoc’s (NYSE:TDOC) Q3 Earnings Results: Revenue In Line With Expectations
Update: 2025-10-30
Description
Teladoc Health met revenue expectations but faced a slight drop in sales and a wider loss per share in Q3 2025. Despite slow growth and flat sales predictions, the company raised its adjusted EBITDA guidance. However, full-year loss guidance missed expectations, leading to a stock dip. Investors question the demand for Teladoc's services amidst increasing competition and flat profits.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
